FDA WARNING_LETTER - ABCO Laboratories, Inc. - September 09, 2011
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA conducted an inspection of ABCO Laboratories, Inc. from August 26 to September 9, 2011, identifying significant violations.
"IBU-RELIEF 12" was found to be an unapproved new drug under Sections 201(g)(1)(C) and 201(P) of the Act [21 U.S.C. §§ 321(g)(1)(C), 321(P)], violating Sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]. Despite being labeled homeopathic, it contains ibuprofen, which is not a recognized homeopathic ingredient, thus not qualifying for CPG 7132.15 enforcement policies.
"Sexual Virility Max" was also deemed an unapproved new drug under Sections 201(g)(1)(C) and 201(P) [21 U.S.C. §§ 321(g)(1)(C), 321(P)], violating Sections 301(d) and 505(a) [21 U.S.C. §§ 331(d), 355(a)]. Laboratory analysis confirmed undeclared sulfoaildenafil and sulfosildenafil,
ID · 3808e62e-cc1d-472d-a2dc-968c0ebe0659
Full citation text and observation details available on the Dashboard.